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Abstract
Background: There are limited therapeutic options for hepatocellular carcinoma (HCC), the most common liver
malignancy worldwide. Recent studies have identified the Frizzled-7 receptor (FZD7), important for activation of
Wnt-mediated signaling, as a potential therapeutic target for HCC and other cancers.
Methods: We hypothesized that the extracellular domain of FZD7 (sFZD7) would be a clinically more relevant
therapeutic modality than previously studied approaches to target FZD7. We expressed and purified sFZD7 from
E. coli, and tested its functional activity to interact with Wnt3, its ability to inhibit Wnt3-mediated signaling, and its
potential for combinatorial therapy in HCC.
Results: sFZD7 pulled down Wnt3 from Huh7 cells, and decreased b-catenin/Tcf4 transcriptional activity in HCC
cells. In vitro, sFZD7 dose-dependently decreased viability of three HCC cell lines (HepG2, Hep40, and Huh7, all with
high FZD7 and Wnt3 mRNA), but had little effect on normal hepatocytes from three donors (all with low level
FZD7 and Wnt3 mRNA). When combined with doxorubicin, sFZD7 enhanced the growth inhibitory effects of
doxorubicin against HCC cells in vitro, and against Huh7 xenografts in vivo. Reduced expressions of c-Myc, cyclin
D1, and survivin were observed in vitro and in vivo. Additionally, sFZD7 altered the levels of phosphorylated AKT
and ERK1/2 induced by doxorubicin treatment in vitro, suggesting that several critical pathways are involved in the
chemosensitizing effect of sFZD7.
Conclusions: We propose that sFZD7 is a feasible therapeutic agent with specific activity, which can potentially be
combined with other chemotherapeutic agents for the improved management of HCC.
Background
The Wnt/b-catenin signaling pathway is commonly dys-
regulated in various cancers, including hepatocellular
carcinoma (HCC) [1]. Aberrations in this pathway have
been established to be critical contributors towards
hepatocarcinogenesis [2]. In 18-67% of HCC tumors,
activation of this cascade, and subsequent accumulation
of nuclear and cellular b-catenin has been observed
[3,4]. However, mutations of b-catenin are detected only
in 20-30% of HCC [3-7]; and loss-of-function mutation
of negative regulators axin1 and axin2 are rare in HCC
[8-10]. These observations suggest that other upstream
elements may be important in the activation of
canonical Wnt/b-catenin during hepatocarcinogenesis,
such as promoter methylation of secreted frizzled-related
protein (SFRP) members [11], and over-expression of
frizzled (FZD) receptors [12-14].
FZDs are frequently upregulated in tumor cell lines and
tissues [1]. All ten members of the FZD family have a
highly conserved N-terminal extracellular, cysteine-rich
domain for Wnt ligand binding, a seven-transmembrane
linker domain, and a C-terminal cytoplasmic domain that
is essential for receptor signaling [15]. In HCC, FZD7 was
shown to be markedly upregulated in four transgenic
mouse models of HCC [16], and in human tumors [12,13].
The over-expression of FZD7 in surrounding peritumoral
and dysplastic liver tissues suggested its involvement in
early events in hepatocarcinogenesis [13,16]. Specifically,
functional interaction between FZD7 and the Wnt3 ligand,
leading to increased nuclear b-catenin accumulation, has
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[12].
The extracellular domain of FZD receptors serves as
binding sites for Wnt ligands (most Wnt ligands will
bind to multiple FZDs and vice versa). This interaction
is indispensable for the activation of Wnt/b-catenin sig-
naling, and interference with this interaction offers a
feasible approach to modulate Wnt/b-catenin activation
in cancers. SFRPs, encoding only the extracellular
domain of FZD, act as natural antagonists of the Wnt/
b-catenin pathway by binding to Wnt ligands and inhi-
biting their interactions with FZDs [17]. Recent studies
have shown that the expression of some SFRP proteins
are inhibited in HCC tissues due to promoter methyla-
tion [14], and that the restoration of SFRP1 could inhi-
bit HCC cell growth by blocking the Wnt/b-catenin
pathway [11]. Additionally, artificial transfection of a
plasmid expressing the FZD extracellular domain antag-
onizes canonical Wnt/b-catenin signaling [18] and even
induces morphological change and attenuates tumor
growth in colon cancer cell lines [19]. More recently,
Ueno et al. demonstrated that siRNA against FZD7
could decrease survival, invasion, and metastatic capabil-
ity of colon cancer cells [20].
Our study investigates a more readily translatable
method to interfere with FZD7/Wnt3 interaction, by using
the extracellular peptide of FZD7 (named soluble FZD7 or
sFZD7) expressed and purified from E. coli to inhibit
Wnt/b-catenin-mediated signaling in human HCC cell
lines. The sFZD7 peptide selectively decreased viability of
HCC cells, but not of normal hepatocytes. Additionally, it
inhibited downstream b-catenin/Tcf4 interaction and tran-
scriptional activity regardless of b-catenin status (wild-type
or mutant). In vitro and in vivo, sFZD7 enhanced the
growth inhibitory effects of doxorubicin, possibly via
down-regulation of target genes of Wnt/b-catenin signal-
ing (c-Myc, cyclin D1, and survivin), and also via modula-
tion of the AKT and ERK pathways. Our data suggest that
the sFZD7 peptide may allow improved clinical manage-
ment of HCC, especially when used in combination with
standard chemotherapeutic agents.
Results
sFZD7 peptide binds to Wnt3 ligand and suppresses
Wnt3-mediated b-catenin transcriptional activation in
Huh7 cells
FZD7 over-expression in HCC implies an activated, FZD7-
mediated Wnt/b-catenin signaling [13]. We hypothesized
that an extracellular domain peptide of FZD7 (soluble
FZD7, sFZD7) will be able to bind extracellular Wnt
ligands, thereby reducing ligand interactions with FZD7
and inhibiting Wnt/b-catenin signaling in HCC. Using E.
coli, we expressed and purified sFZD7 with an apparent
molecular weight of 27 kDa on SDS-PAGE (Figure 1A).
As a first step to test the functional activity of sFZD7, we
used the pull-down assay to demonstrate that sFZD7 was
able to bind to Wnt3 (a reported ligand of FZD7) in Huh7
cells (Figure 1B). Using the b-catenin/Tcf4 transcriptional
reporter (TOP/FOPFLASH) luciferase assay in Huh7 cells,
we observed that Wnt3 increased b-catenin transcriptional
activity, either alone (2-fold, P < 0.05) or in combination
with FZD7 (3-fold, P < 0.001). Treatment with sFZD7 sig-
nificantly abolished the Wnt3-induced activation of b-
catenin/Tcf4 transcriptional activity (Figure 1C, *P < 0.05),
further confirming that sFZD7 is functionally active.
sFZD7 inhibits Wnt/b-catenin transcriptional activity and
suppresses the expression of downstream oncoproteins
To determine the ability of sFZD7 to disrupt Wnt/b-catenin
signaling in HCC cells, we first looked at its effect on
nuclear b-catenin accumulation. Treatment of Huh7 and
HepG2 cells with different concentrations of sFZD7 for 48 h
decreased nuclear b-catenin accumulation in both cell lines,
but did not affect cytoplasmic b-catenin level. In HepG2
cells that harbor both wild type and truncated b-catenin
[21], sFZD7 decreased the level of wild type b-catenin only,
with negligible effect on the truncated b-catenin level (Fig-
ure 2A). Additionally, 48 h treatment with sFZD7 caused
dose-dependent decreases in b-catenin/Tcf4 transcriptional
activities in both Huh7 and HepG2 cells (Figure 2B). Consis-
tently, the endogenous levels of b-catenin/Tcf4 regulated
proteins (c-Myc, cyclin D1, and survivin) were reduced after
48 h treatment with sFZD7 (2 μg/ml) in Huh7 and HepG2
cells (Figure 2C). These three proteins are known to be
over-expressed in HCC [22-24], and our results indicate that
their expression is regulated by Wnt/b-catenin signaling.
sFZD7 decreases viability of hepatoma cells but not
normal hepatocytes
The inhibitory effects of sFZD7 on the growth promot-
ing, Wnt/b-catenin signaling in hepatoma cells suggest
that sFZD7 might influence cell viability. We observed
that sFZD7 dose-dependently decreased viability of
three HCC cell lines (with high FZD7 and Wnt3 expres-
sion) after 72 h treatment, but did not affect normal
hepatocytes (with low FZD7 and Wnt3 expression) from
three donors (Figure 3A). The correlation between the
growth inhibitory effect of sFZD7 and cellular FZD7
and Wnt3 mRNA levels (Figure 3B) provide further sup-
port that sFZD7 is acting specifically via the FZD7-
mediated Wnt/b-catenin signaling in HCC cells, and
that it exerts preferential activity against HCC cells
over-expressing FZD7 and Wnt3.
sFZD7 sensitizes HCC cells to the anti-proliferative effect
of doxorubicin in vitro
Since the Wnt/b-catenin signaling pathway has been
implicated in chemoresistance of cancer cells [25-28],
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cells to the standard chemotherapeutic agent doxorubi-
cin. We demonstrate that sFZD7 (at 2 μg/ml) signifi-
cantly decreased the IC50 value of doxorubicin in Huh7
cells from 0.10 ± 0.02 μM to 0.05 ± 0.01 μM, P < 0.05;
and the IC50 value of doxorubicin in HepG2 cells from
7.42 ± 0.90 μM to 4.66 ± 0.52 μM, P < 0.05 (Figure 4A,
Table 1). Because doxorubicin itself had negligible
effects on the expression of c-Myc, cyclin D1 or survi-
vin, we further detected the activation states of AKT
and ERK1/2 in Huh7 and HepG2 cells after treatment
with sFZD7 and doxorubicin, since these two pathways
are also stimulated by Wnt proteins [29]. In both cell
lines, doxorubicin alone induced a significant increase in
phospho-AKT level (Figure 4B), which was reduced
when sFZD7 was combined with doxorubicin (Figure 4B).
Total AKT levels were unchanged. Doxorubicin alone
also induced the levels of phospho-ERK1/2; however,
when sFZD7 was combined with doxorubicin, phos-
pho-ERK1/2 levels were further enhanced without
affecting total ERK levels (Figure 4B). Complex cross-
talk among these critical pathways (Wnt, AKT, ERK)
may together account for the chemosensitizing effect
of sFZD7.
sFZD7 sensitizes HCC cells to the anti-proliferative effect
of doxorubicin in vivo
In vivo, 14-days treatment with sFZD7 only, Doxil only,
or sFZD7 combined with Doxil caused significantly
delayed tumor growth in Huh7 xenografts in nude mice,
Figure 1 sFZD7 binds to Wnt3 and suppresses Wnt3-induced b-catenin/Tcf4 transcriptional activation in Huh7 cells.( A). SDS-PAGE
analysis of purified sFZD7. (B). Pull-down assay demonstrating the interaction between sFZD7 and Wnt3. Huh7 cells lysate was pulled down with
Ni-NTA agarose with or without recombinant His-sFZD7 peptide. Protein complexes were centrifuged and eluted, and the supernatants analyzed
by Western blot using rabbit anti-Wnt3 antibody (upper panel) and anti-His antibody (lower panel). Huh7 lysate and recombinant His-sFZD7
were used as positive controls. (C). sFZD7 abolished the Wnt3-induced b-catenin/Tcf4 transcriptional activity in Huh7 cells. Huh7 cells were
transfected with 0.2 μg of each of the indicated expression plasmid, along with 0.3 μg of pTOPFLASH or pFOPFLASH reporter plasmids and 0.1
μgo fb-gal to normalize for transfection efficiency. The results are expressed as means ± SD (error bars) of triplicate assays. *P < 0.05 versus
control.
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dent sample t-test, P = 0.048 for sFZD7 only; P = 0.041
for Doxil only; P = 0.001 for sFZD7 plus Doxil). Addi-
tionally, the sFZD7 plus Doxil group showed signifi-
cantly reduced tumor growth when compared with
other treatment groups at day 17 of treatment (P =
0.041, compared with sFZD7 only; P = 0.035, compared
with Doxil only).
Tumor xenografts were harvested for TUNEL staining
at the end of the treatment period, and apoptotic cells
were detected in tumors treated with sFZD7, Doxil, or
sFZD7 combined with Doxil (Figure 5B). Whereas the
PBS control tumors have less than 10% apoptotic cells,
there were between 10-30% apoptotic cells in the sFZD7
or Doxil single treated tumors, and more than 50%
apoptotic cells in the sFZD7 and Doxil combined
Figure 2 sFZD7 inhibits Wnt/b-catenin signaling and suppresses the expression of downstream oncoproteins.( A). sFZD7 decreased
nuclear b-catenin accumulation but did not decrease cytoplasmic b-catenin in Huh7 and HepG2 cells. Histone-H3 and b-actin were used as
loading controls for nuclear and cytoplasmic proteins, respectively. (B). Tcf4 reporter assay of Tcf4-dependent transcriptional activity in Huh7 and
HepG2 cells. Cells were co-transfected with plasmid encoding b-gal (a control for transfection efficiency) and either the pTOPFLASH or
pFOPFLASH reporters. Cells were incubated with control PBS or sFZD7 at various concentrations and harvested after 48 h to measure luciferase
and b-gal activities. Reporter gene activation is expressed as relative light units (RLU) detected in pTOPFLASH or pFOPFLASH transfected cells
and normalized for b-galactosidase activity. The results are expressed as mean ± SD (error bars). Experiments were performed in triplicates
(Independent t-test, *P < 0.05.) (C). The effect of sFZD7 on the expression of b-catenin/Tcf4 target genes c-Myc, cyclin D1, and survivin. Huh7
and HepG2 cells were incubated for 48 h with sFZD7 at various concentrations and c-Myc, cyclin D1, survivin, and b-actin (loading control) levels
were determined by Western blotting using specific antibodies.
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survivin were visualized by immunostaining and Wes-
tern blotting (Figure 5C-E). While Doxil itself had negli-
gible effect on the expression of c-Myc, cyclin D1, or
survivin, sFZD7 alone or in combination with Doxil
decreased the tumor levels of these three downstream
target proteins of Wnt/b-catenin signaling. This is con-
sistent with our in vitro observations that sFZD7 inhib-
ited b-catenin/Tcf4 mediated transcriptional activity,
which might contribute to the observed tumor growth
inhibition by sFZD7, and its chemosensitizing effect
with Doxil.
Discussion
HCC patients typically have a dismal prognosis, espe-
cially if they are diagnosed late. The rising incidence of
HCC (the fifth most common cancer globally), and the
current lack of effective systemic treatment options,
makes it imperative to develop novel and efficacious
treatment strategies to overcome current challenges,
which include intrinsic resistance to standard che-
motherapeutic agents. Recent advances in HCC pathol-
ogy have identified activated signaling pathways as new
therapeutic targets [30-32]. The Wnt/b-catenin pathway
and its many components are especially attractive tar-
gets because of their functional importance in hepato-
carcinogenesis. Among them, FZD7 has been considered
a promising therapeutic target [20,33] because FZD7
mediated Wnt/b-catenin signaling is closely associated
with growth and survival of tumor cells [8,34]. Addition-
ally, elevated FZD7 mRNA levels have been reported in
HCC and other cancers [12,13,35-39]. Our study
explores the use of a purified, soluble ectodomain pep-
tide of FZD7 (sFZD7, containing the cysteine-rich
domain that interacts with Wnt ligands) as a new thera-
peutic modality for inhibiting FZD7/Wnt-mediated sig-
naling in HCC.
We first confirmed the functional activity of sFZD7 by
demonstrating its ability to bind to its known ligand,
Wnt3, using a pull-down assay in Huh7 cells. Addition-
ally, sFZD7 blocked Wnt3-induced b-catenin/Tcf4 tran-
scriptional activation in Huh7 cells, confirming its
functional activity. In Huh7 and HepG2 cells, sFZD7
caused dose-dependent inhibitions of nuclear b-catenin
accumulation and b-catenin/Tcf4 transcriptional activity,
together with reduced expressions of downstream target
genes c-Myc, cyclin D1, and survivin. These effects of
sFZD7 might underlie its growth inhibitory effects
against three hepatoma cell lines (with high expression
of FZD7 and Wnt3 mRNA), but not against normal pri-
mary hepatocytes (with low expression of FZD7 and
Wnt3 mRNA). Our results also suggest that sFZD7
exerts inhibitory effects on Wnt/b-catenin signaling and
cell growth regardless of b-catenin status (wild type or
mutant). HepG2 cells, which are known to have a con-
stitutively active, truncated mutant of b-catenin lacking
the GSK-3b regulatory site [21], respond similarly to
sFZD7 treatment as do Huh7 cells with wild type
b-catenin. Whether the truncated b-catenin could be
Figure 3 sFZD7 decreases viability of hepatoma cells but not
of normal hepatocytes.( A). Cell viability assay based on cellular
ATP content was used to determine the in vitro activity of sFZD7 on
three human HCC cell lines and normal hepatocytes from three
donors following 72 h of sFZD7 treatment (Independent t test, *P <
0.05). Three independent experiments were done, each in triplicates.
(B). The relative FZD7 and Wnt3 mRNA levels were detected in HCC
cell lines and normal hepatocytes from three donors. Data are
represented as means ± SD (error bars) from triplicate experiments.
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Shih et al. observed that restoration of SFRP attenuated
Wnt signaling in Huh6 cells (with a b-catenin point
mutation), but not in HepG2 cells with truncated
b-catenin [11]. However, our findings are consistent
with those of Hocevar et al., who observed that the
stable over-expression of Dab2, which stabilizes axin as
a binding partner of Dvl-3 and axin, decreased nuclear
b-catenin accumulation and inhibited b-catenin tran-
scriptional activity in HepG2 cells [40].
In addition to its fundamental roles in tumor cell
growth and survival, the Wnt/b-catenin signaling path-
way is also implicated in the development of chemore-
sistance in a wide variety of cancer cells [25-28]. Since
HCC is highly chemoresistant and lacks effective thera-
peutic options [41], we tested the ability of sFZD7 to
sensitize HCC cells to treatment with doxorubicin, com-
monly used for treating HCC. In vitro, sFZD7 sensitized
Huh7 and HepG2 cells to the anti-proliferative effects of
doxorubicin. In vivo, combined sFZD7 and Doxil treat-
ment significantly augmented the growth inhibitory
effects of either sFZD7 alone or Doxil alone on HCC
xenografts. This observation may in part be due to the
ability of sFZD7 to reduce the expression of survivin, a
Wnt target gene that is over-expressed in HCC, and
also a key regulator of cell division and inhibitor of
apoptosis that has been demonstrated to be involved in
tumor chemoresistance [42]. Additionally, we found that
sFZD7 was able to decrease the levels of phospho-AKT
Figure 4 sFZD7 sensitizes HCC cells to doxorubicin treatment in vitro.( A). sFZD7 sensitizes HCC cells to anti-proliferative effect of
doxorubicin in vitro. Huh7 and HepG2 were treated with various concentrations of doxorubicin with or without sFZD7 (2 μg/ml) for 72 h, and
cell proliferation determined as described under Materials and Methods. Data are means ± SD (error bars). (B). The effect of sFZD7 on the
activation of AKT and ERK1/2 induced by doxorubicin. Huh7 and HepG2 cells were incubated with sFZD7 (10 μg/ml) for 48 h, and then
doxorubicin (2.5 μM) was added for another 6 h. The phospho-AKT, total AKT, phospho-ERK1/2, total ERK1/2, and b-actin (loading control) levels
were determined by Western blotting using specific antibodies.
Table 1 IC50 values for doxorubicin with or without
sFZD7 in human heptaoma cell lines following 72 h of
drug treatment in vitro
Cell
line
IC50 (μM)
Doxorubicin only
IC50 (μM) Doxorubicin
+sFZD7 (2 μg/ml)
Sensitivity
Index
Huh7 0.10 ± 0.02 0.05 ± 0.01* 2.00
HepG2 7.42 ± 0.90 4.66 ± 0.50* 1.59
Values are expressed as mean ± SD. The chemosensitizing effects of
doxorubicin in combination with sFZD7 are expressed as the sensitivity index
(Mean IC50 value for doxorubicin alone/Mean IC50 value for doxorubicin +
sFZD7). Independent T-test was used to compare the IC50 values of
doxorubicin alone or in combination with sFZD7; * P < 0.05 in both cell lines.
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recent report by Ohigashi et al, who showed that inhibi-
tion of Wnt signaling by the Wnt inhibitory factor-1
down-regulated the AKT pathway, leading to enhanced
chemosensitivity in PTEN-null prostate cancer cells
[43]. Activation of the AKT pathway has been reported
to be involved in the activation of Wnt/b-catenin signal-
ing pathway [29] and implicated in the development of
acquired drug resistance [44]. Thus, we propose that
sFZD7 might decrease survivin expression and inhibit
the activation of AKT pathway, thereby contributing
towards doxorubicin sensitization in HCC cells.
Figure 5 sFZD7 sensitizes HCC cells to the anti-proliferative effect of doxorubicin in vivo.( A). Combination of sFZD7 and Doxil enhanced
xenograft growth inhibition in vivo. Mice bearing Huh7-tumor xenografts were intratumorally injected weekly with PBS control; sFZD7 only (12.5
mg/kg); Doxil only (2.5 mg/kg); or sFZD7 (12.5 mg/kg) combined with Doxil (2.5 mg/kg) (n=5 in each treatment group). Tumor size was
measured with digital calipers every three days. Significant differences in the tumor volumes between all treatment groups and the PBS control
were observed after 14 days of treatment (*P < 0.05). Additionally, the sFZD7 plus Doxil combination group showed significant differences in
tumor volumes compared with sFZD7 only or Doxil only groups after 17 days of treatment (*P < 0.05). (B). TUNEL staining of xenograft
specimens removed from PBS control and all treatment groups (200 × magnification). Red arrows indicate some positively stained, apoptotic
cells. (C). Representative cyclin D1 immunostaining of xenograft specimens removed from PBS control and all treatment groups are shown (200
× magnification). (D). Protein levels of c-Myc, cyclin D1, survivin, and b-actin (loading control) in tumor xenografts from two mice in each group
were determined by Western blotting using specific antibodies. (E). The expression levels of c-Myc, cyclin D1, survivin were determined by
analyzing Western blots with the ImageJ software, and normalizing their signal intensities to b-actin.
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talks among critical pathways (Wnt, AKT, ERK) that are
involved in HCC. An increase in phosphorylation of
ERK1/2 was previously observed in HCC cells treated
with doxorubicin, as early as 30 min and up to 24 h
after treatment, while total ERK levels were unchanged
[45]. Earlier studies in other cell types concur with the
ability of the doxorubicin and other DNA-damaging
agents (such as etoposide) to induce ERK activation
[46-49]. Activation of ERK in response to DNA damage
might occur via p53-dependent or p53-independent
(ATM-dependent) pathways, which then act coopera-
tively in enhancing cell cycle arrest and apoptosis
[48-51]. In our study, sFZD7 further increased the ERK
activation induced by doxorubicin in both HepG2 (wild-
type p53) and Huh7 (mutant p53) cells, and may
enhance sensitivity to doxorubicin by increasing cell
cycle arrest and/or apoptosis.
Conclusion
Given the emerging interest in peptide-based cancer
therapeutics, and recent advances in improving peptide
stability and delivery [52,53], we propose that the sFZD7
peptide is a feasible therapeutic agent that can be used
to specifically abolish the functional activity of FZD7 in
HCC. It has potential wide applicability in the treatment
of HCC, especially when used in combination with
agents targeting other components of the Wnt/b-catenin
signaling pathway, or with standard chemotherapeutic
agents to increase drug sensitivity by modulating the
activities of essential pathways in HCC. Further clinical
translation of the sFZD7 peptide will require optimiza-
tion of the peptide size and physicochemical properties
to achieve desirable bioavailability [54].
Materials and methods
Cell lines and primary cultures of hepatocytes
Human hepatoma cell lines (Huh7, HepG2, Hep40)
were maintained in Dulbecco’s Modified Eagle’sM e d -
ium (DMEM) supplemented with 10% fetal bovine
serum (FBS), 100 μg/mL penicillin and 100 μg/mL
streptomycin. All media and supplements were from
Invitrogen (Carlsbad, CA). Cells were maintained at 37°
C in a humidified atmosphere with 5% CO2.
Cryopreserved human hepatocytes, collagen-coated 96-
well plates, CHRM Thawing Medium, Cell Plating Med-
ium, and Cell Maintenance Medium were received from
CellzDirect/Invitrogen (Durham, NC). Characteristics of
the hepatocytes and the plating method are as described
previously [55].
Plasmids
Human Wnt3 cDNA clone pUSEamp-Wnt3 (HA-Wnt3)
and the empty vector pUSEamp were from Millipore
(Billerica, MA). pCMV6-XL5-FZD7 and the empty vec-
tor pCMV-XL5 were from OriGene Technologies
(Rockville, MD). TCF/Luc reporter constructs, pTOP-
FLASH (wild type) and pFOPFLASH (mutant), were
from B Vogelstein (John Hopkins Oncology Center, Bal-
timore, MD, USA). The pet28A-sFZD7 was constructed
by cloning the PCR-amplified product of the sFZD7
coding region into the BamHI and HindIII sites of vec-
tor pet28A (Merck Biosciences, Darmstadt, Germany).
sFZD7 fragment was amplified using template contain-
ing full length FZD7 plasmid with the following primers:
upstream (5’-TTTGGATCCTGCCAGCCCATCTCCAT-
3’), and downstream (5’-TTTAAGCTTCACCGGG-
TGCGGGCGAAGCGCCTCT-3’). The PCR reaction
was performed in a GeneAmp PCR system 2700
(Applied Biosystems, Foster City, CA) under the follow-
ing conditions: heat activation of the polymerase for
5 min at 94°C, followed by 30 cycles of 95°C for 30 sec,
58°C for 30 sec, and 72°C for 45 sec; with a final exten-
sion at 72°C for 10 min.
Expression and purification of sFZD7
Recombinant His-sFZD7 peptide was produced in E. coli
(strain BL21, DE3) with IPTG induction, and purified
from the insoluble fraction of the bacterial lysate with
Ni-NTA (Qiagen, Carpinteria, CA) following the manu-
facturer’s instructions. Elution was done with 8 M urea
elution buffer (pH 4.0). Eluted His-sFZD7 fusion protein
was dialyzed against phosphate-buffered saline (PBS)
with a stepwise increasing pH gradient (pH 4.0 to pH
7.4) at 4°C. The concentration of final His-sFZD7 fusion
peptide was determined by BCA protein assay (PIERCE,
Rockford, IL) and purification was confirmed by SDS-
PAGE and immunoblotting using HRP-labeled anti-His
tag antibody (1:1000, Abcam, Cambridge, MA).
Pull down assay
Huh7 cells (5 × 10
6) were lysed in RIPA buffer and the
crude lysate was clarified by centrifugation at 12,000 × g
for 5 min. Recombinant His-sFZD7 peptide (100 μg)
was mixed with 15 μl Ni-NTA agarose beads (Qiagen,
Carpinteria, CA) in binding buffer (50 mM NaH2PO4,
300 mM NaCl, 10 mM imidazole, pH 8.0) and incu-
bated for 1 h with gentle rotation, and then washed
with wash buffer (50 mM NaH2PO4,3 0 0m MN a C l ,
40 mM imidazole, pH 8.0). The Ni-NTA agarose with
recombinant His-sFZD7 peptide was mixed with Huh7
cell lysate; mock agarose was separately mixed with
Huh7 cell lysate. Imidazole was added to the mixtures
at a final concentration of 40 mM, and incubated over-
night with gentle rotation in 4°C. After centrifugation at
400 × g for 2 min at 4°C, supernatants were discarded
and the agarose mixtures were washed with binding buf-
fer three times for 5 min each. The agarose mixtures
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buffer (50 mM NaH2PO4, 300 mM NaCl, 250 mM imi-
dazole, pH 8.0) and the supernatants were resolved on
S D S - P A G E .W e s t e r nb l o t sw e r ed o n eu s i n gt h er a b b i t
anti-Wnt3 (1:1000, Abcam, Cambridge, MA), and anti-
His tag (1:1000, Abcam, Cambridge, MA) antibodies.
Luciferase reporter gene assay
Huh7 cells (at 50% confluency) were transfected with
0.2 μg of HA-Wnt3 or empty vector and 0.2 μgo f
pCMV6-XL5-FZD7 or the empty vector, along with
0.3 μg of pTOPFLASH or pFOPFLASH reporter plas-
mids and 0.1 μgo fb-gal to normalize for transfection
efficiency. The amount of DNA in each transfection
reaction was kept constant by adding an appropriate
amount of the empty vector. Transfection was per-
formed using Lipofectamine 2000 (Invitrogen, Carlsbad,
CA) according to the manufacturer’s instructions. After
4 h, media containing transfection reagent were replaced
with new culture media with or without sFZD7 (2 μg/ml).
After 48 h, cells were lysed in 100 μl of lysis buffer, and
20 μl aliquots were assayed using the Promega Luciferase
assay system, and the Promega b-gal assay system. Rela-
tive light units (RLU) were measured and normalized for
transfection efficiency using b-gal activity. Final RLU
representing Tcf4 transcriptional activity were calculated
by subtracting normalized levels obtained with pFOP-
FLASH from those obtained with pTOPFLASH.
Protein extracts and immunoblotting
Huh7 and HepG2 cells were seeded at 50% confluency in
6-well plates and incubated at 37°C overnight. Cells were
then treated with PBS, or with purified sFZD7 at desired
concentrations (2, 10, or 20 μg/ml) for 48 h. Cell mono-
layers were washed twice with PBS and then lysed in the
RIPA extraction buffer. For nuclear b-catenin immunode-
tection, nuclear extracts were prepared with a NE-PER
Nuclear and Cytoplasmic Extraction Kit (Pierce, Rockford,
IL). Equal amounts of protein (20 μg) were resolved by
SDS-PAGE and Western blots were performed by using
the primary antibodies to c-Myc (1:500, Cat. No. 551101,
BD Pharmingen, San Diego, CA), cyclin D1 (1:1000, Cat.
No. ab6152, Abcam, Cambridge, MA), survivin (1:1000,
Cat. No. NB500-201H, Novas Biologicals, Littleton, CO),
b-catenin (1:500; Cat. No. SC-7963, Santa Cruz Biotech-
nology Inc., Santa Cruz, CA), HRP-Histone H3 (1:10000,
Cat. No. Ab21054, Abcam, Cambridge, MA) and HRP-b-
actin (1:10000, Cat. No. A3854, Sigma-Aldrich, MO). Sec-
ondary antibodies (anti-mouse, Cat. No. SC-2005 and
anti-rabbit, Cat. No. SC-2004) conjugated with horseradish
peroxidase were from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA).
For sFZD7 and doxorubicin combination treatment,
Huh7 and HepG2 cells were treated with PBS, purified
sFZD7 alone (10 μg/ml for 48 h), doxorubicin alone
(2.5 μM for 6 h), or combination of sFZD7 and doxoru-
bicin (10 μg/ml of sFZD7 for 48 h, followed by addition
of 2.5 μM doxorubicin for 6 h). Cell monolayers were
then lysed in the RIPA extraction buffer. Equal amounts
of total cell protein (20 μg) were resolved by SDS-PAGE
and Western blots were performed by using the primary
antibodies to ERK1/2 (1:1000, Cat. No. 9102, Cell Sig-
naling Technology Inc., Danvers, MA), p-ERK1/2
(1:1000, Cat. No. 4370, Cell Signaling Technology Inc.,
Danvers, MA), AKT (1:1000, Cat. No. 9272, Cell Signal-
ing Technology Inc., Danvers, MA), p-AKT (1:1000, Cat.
No. 4058s, Cell Signaling Technology Inc., Danvers,
MA).
Quantitative real-time PCR assay
Total RNA was extracted from hepatoma cells and
h e p a t o c y t e sb yu s i n gt h eR N e a s ym i n ik i t( Q i a g e n ,
Valencia, CA) following the manufacturer’si n s t r u c t i o n s .
Concentration and purity of extracted RNA were deter-
mined by optical density measurement at 260 and
280 nm. All real-time PCR reagents were from Applied
Biosystems (Foster city, CA). Briefly, first-strand cDNA
was generated by random primers using Taqman
Reverse Transcriptional Reagent, and real-time PCR was
performed by using Taqman Gene Expression Assay
(Human FZD7 assay ID: Hs00275833_s1; Human Wnt3
assay ID: Hs00229135_m1) and Universal PCR Master
Reagent in a Stratagene Mx3000P Q-PCR system (Stra-
tagene, La Jolla, CA). These reactions were incubated
at 95°C for 10 min, followed by 40 cycles at 95°C for
15 sec, and 60°C for 1 min. The expression level of
FZD7 was measured in terms of threshold cycle value
using Stratagene MxPro software and normalized to the
internal control, human 18s rRNA (Part No. 4333760F).
Cell viability assay
Hepatoma cells were seeded in 96-well plates at 3 × 10
3
cells/well, and normal hepatocytes seeded at 3 × 10
4
cells/well, and incubated overnight at 37°C prior to
addition of sFZD7 at desired final concentrations (range
from 1.25-20 μg/ml). Cells were further incubated for 72
h before cell viability was assessed using CellTiter-Glo
Luminescent Cell Viability Assay (Promega, Madison,
WI) according to the manufacturer’s instructions. Luci-
ferase activity was measured on a luminometer (Bert-
hold LB-96V) and values were normalized to the ATP
activity and compared with the PBS control value,
which was set at 100. Three independent experiments
were done, each in triplicates.
Cell proliferation assay
Hepatoma cells were seeded in 96-well plates at 3 × 10
3
cells/well, maintained overn i g h ta t3 7 ° C ,a n di n c u b a t e d
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from 0-100 μM) with or without sFZD7 (2 μg/ml). After
72 h incubation, cell proliferation was monitored by
using CellTiter 96
® AQueous One Solution Cell Prolif-
eration Assay (Promega, Madison, WI) according to the
manufacturer’s instructions. Optical density (OD) at
490 nm was read using a microplate reader (BioTek
I n s t r u m e n t s ,I n c . ,W i n o o s k i ,V T ) .T h e5 0 %i n h i b i t o r y
concentrations (IC50s) were calculated as an estimate of
the anti-proliferative effects of doxorubicin alone or in
combination with sFZD7.
Xenografts in nude mice
Animal experiments were approved by the Administra-
tive Panel on Laboratory Animal Care at Stanford
University. Nude mice (ATHYMIC NU/NU; Harlan
Sprague-Dawley, Indianapolis, IN) at age 4-6 weeks
( b o d yw e i g h to f1 8t o2 5g )w e r eu s e d .M i c ew e r e
injected subcutaneously at the dorsal region with 5 ×
10
6 viable Huh7 cells. After two weeks, when tumors
reached approximately 0.4-0.5 cm in diameter, mice
were randomized into four groups (n = 5 each) to be
intratumorally injected with (1). PBS control (100 μl,
once weekly); (2). purified sFZD7 (dose:12.5 mg/kg;
volume: 100 μl; once weekly); (3). Doxil (dose: 2.5 mg/
kg; volume: 100 μl; once weekly); or (4). sFZD7 (dose:
12.5 mg/kg; volume: 100 μl; once weekly) plus Doxil
(dose: 2.5 mg/kg; volume: 100 μl; once weekly). Doxil is
a liposomal formulation of doxorubicin for intravenous
use. Intratumor administration was chosen to mimic the
clinically used treatment method of chemoembolization,
which delivers cytotoxic drugs directly to the HCC
tumor for greater efficacy and reduced toxicity. Tumor
size was measured with digital calipers every three days
and was calculated using the formula π/6 × larger dia-
meter × [smaller diameter]
2. Mice in the PBS group
were sacrificed after 14 days, whereas mice in other
treatment groups were sacrificed after 17 days of treat-
ment. Tumor tissues were harvested for immunohisto-
chemistry as described below, and for TUNEL staining
using the ApopTag Peroxidase in Situ Oligo Ligation
Apoptosis Detection Kit (Chemicon International,
Temecula, CA) according to the manufacturer’sp r o t o -
col. We assessed the percentage of cells that stained
positively with brown nuclei in five randomly selected
areas of 100 cells per area. Western blot was used to
quantify the protein levels of c-Myc, cyclin D1, or survi-
vin in tumor xenografts of two mice in each group. The
antibodies used were: HRP-conjugated anti c-Myc
(1:1000, Cat. No. ab62928, Abcam, Cambridge, MA),
biotin-conjugated anti-cyclin D1 (1:1000, Cat. No. MS-
210-B0, Thermo Scientific, Fremont, CA), HRP-conju-
gated anti-survivin (1:1000, Cat. No. NB500-201H,
Novas Biologicals, Littleton, CO), HRP-conjugated
b-actin (1:10000, Cat. No. A3854, Sigma-Aldrich,
S t .L o u i s ,M O ) ,a n ds e c o n d a r y antibodies (anti-biotin)
conjugated with HRP (1:1000, Cat. No. Ab19221-1,
Abcam, Cambridge, MA). Western blots were analyzed
by ImageJ software, and signal intensities normalized to
b-actin.
Immunohistochemistry analysis
Immunoperoxidase staining of tumor xenografts was per-
formed on formalin-fixed 4-μmt i s s u es e c t i o n .B r i e f l y ,
sections were incubated with monoclonal mouse anti-
human c-Myc (1:200, Cat. No. 551101, BD Pharmingen,
San Diego, CA), cyclin D1 (1:250, Cat. No. ab6152,
Abcam, Cambridge, MA), or survivin (1:500, Cat. No.
NB500-201H, Novas Biologicals, Littleton, CO) and then
washed with PBS. Subsequent procedures were per-
formed using Dakocytomation Envision System-HRP
mouse system (Dako, Carpinteria, CA) according to the
manufacturer’s protocol.
Statistical analysis
Statistical significance was determined by the indepen-
dent-sample T-test using the computer SPSS software
(version 10.0; SPSS, Chicago, IL). P values less than 0.05
were considered statistically significant.
Abbreviations
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